CN109077993B — 一种泪小管缓释水凝胶植入剂及其制备方法
Assigned to Beijing Nuokangda Pharmaceutical Technology Co ltd · Expires 2021-03-16 · 5y expired
What this patent protects
本发明涉及一种活性成分制剂,具体涉及一种泪小管缓释水凝胶植入剂,该植入剂包括聚乙二醇衍生物水凝胶和活性成分颗粒,所述植入剂以聚乙二醇衍生物水凝胶为基质,活性成分颗粒均匀分布,所述植入剂采用拉伸仪制备。本发明还公开了该植入剂的制备方法。通过控制水凝胶处方与拉伸工艺参数,实现了植入剂规模化生产。凝胶可方便插入泪小管,实现无创植入,提高了患者顺应性。
USPTO Abstract
本发明涉及一种活性成分制剂,具体涉及一种泪小管缓释水凝胶植入剂,该植入剂包括聚乙二醇衍生物水凝胶和活性成分颗粒,所述植入剂以聚乙二醇衍生物水凝胶为基质,活性成分颗粒均匀分布,所述植入剂采用拉伸仪制备。本发明还公开了该植入剂的制备方法。通过控制水凝胶处方与拉伸工艺参数,实现了植入剂规模化生产。凝胶可方便插入泪小管,实现无创植入,提高了患者顺应性。
Drugs covered by this patent
- Decadron (dexamethasone) · Generic (originally Merck)
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.